Cytek Biosciences, Inc. CTKB 深 滬
等待開盤 02-12 09:30:00 美东时间
4.36
+0.050
+1.16%
華盛通- 最 高4.41
- 今 開4.35
- 成交量 71.06万股
- 最 低 4.255
- 昨 收 4.31
- 總市值 5.57亿
- 52周最高 6.18
- 市盈率 靜 --
- 換手率 0.56%
- 52周最低 2.37
- 委 比 69.13%
- 總股本 1.28亿
- 歷史最高 28.70
- 量 比 0.57
- 振 幅 3.60%
- 歷史最低 2.37
- 每 手 1
- 風險率 0.79%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cytek Sees $62M Q4 Revenue, Forecasts About $201M in Full-Year 2025 Sales
Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced preliminary, unaudited revenue results for the fourth quarter and full year ended December 31, 2025.Cytek expects its
01-12 18:08
美股大行评级 | 潜在涨幅197.4%！奥麦罗制药获HC Wainwright升目标价至40美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持奥麦罗制药"买入"评级，目标价从20美元升至40美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从26美元升至27美元
01-09 20:22
TD Cowen Maintains Buy on Cytek Biosciences, Raises Price Target to $5
TD Cowen analyst Brendan Smith maintains Cytek Biosciences (NASDAQ:CTKB) with a Buy and raises the price target from $4 to $5.
01-09 02:16
Legence, Cidara Therapeutics, Avadel Pharmaceuticals, Omeros And Other Big Stocks Moving Higher On Friday
U.S. stocks were lower, with the Dow Jones index falling more than 500 points o...
2025-11-14 22:54
美股大行评级 | CoreWeave、Monday遭美银、小摩等多家大行下调目标价；中金首予Nebius "跑赢大市"评级，目标价143美元
今日重点评级关注：Piper Sandler：维持MeiraGTx Hldgs"超配"评级，目标价从28美元升至30美元；RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从26美元升至32美元
2025-11-12 11:43
电话会总结 ｜ Cytek(CTKB)2025财年Q3业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Cytek业绩会实录，以下是Q3 2025财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** Q3 2025总营收5,230万美元，同比增长2%。产品营收（仪器+试剂）同比下降4%，主要受EMEA地区26%的下滑拖累，但被APAC地区19%的增长部分抵消。服务营收同比增长19%，试剂营收同比增长21%，创下单季度历史新高。 **利润率表现：** GAAP毛利率为53%，较去年同期的56%下降3个百分点；调整后毛利率为55%，较去年同期的60%下降5个百分点。毛利率下降主要由于产品营收减少、材料和关税成本上升以及管理费用增加。 **净利润
2025-11-06 13:33
Cytek Biosciences shares are trading higher after the company reported better-than-expected Q3 financial results.
Cytek Biosciences shares are trading higher after the company reported better-t...
2025-11-06 06:23
Cytek® Biosciences Deepens Commitment to Expanding Access to Flow Cytometry
Cytek Biosciences has launched a two-part research initiative in partnership with ISAC to expand access to flow cytometry worldwide. The first phase involves awarding a three-laser Cytek Northern Lights flow cytometer, while the second phase plans to introduce a grant program to fund research projects. These efforts aim to support under-resourced labs and advance global scientific equity, building on previous collaborations like donating equipmen...
2025-10-29 21:00
Cytek Biosciences Announces The Relocation Of Its European Headquarters To A New Facility In Amsterdam's Life Sciences District
FREMONT, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- In a move that strengthens its European operations and enhances service for its customers, spectral flow cytometry leader Cytek Biosciences, Inc. (NASDAQ:CTKB) today
2025-10-16 05:04
Cytek Biosciences Brings Full Spectrum Cell Analysis to Leading Clinical Global Conferences ICCS and ESCCA
Cytek Biosciences, a leader in spectral flow cytometry, will showcase its advanced solutions at the ESCCA 2025 Conference in Montpellier, France, and ICCS 2025 in Philadelphia. The company's Full Spectrum Profiling™ (FSP®) technology has revolutionized cell biology and diagnostics, enabling high-parameter analysis with reduced reagent use and streamlined workflows. At ESCCA, Joseph Lownik, MD, PhD, will present a workshop on integrating spectral ...
2025-09-10 21:00
